Better treatments for acute myeloid leukemia sought with largest dataset
Researchers have put together the largest dataset of acute myeloid leukemia, featuring 672 samples from 562 patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 17, 2018 Category: Consumer Health News Source Type: news

OHSU-led effort results in largest cancer dataset of its kind
(Oregon Health& Science University) After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, 'Functional Genomic Landscape of Acute Myeloid Leukemia,' published today in Nature. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Vast leukemia dataset could help researchers match therapies to patients
(Howard Hughes Medical Institute) Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Delving Where Few Others Have Gone, Leukemia Researchers Open New Path
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 15, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Breast cancer drug may also work against form of leukemia
A new drug used for advanced breast cancer can also work effectively to treat acute myeloid leukemia, according to a study with mice and cells in a lab. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 9, 2018 Category: Consumer Health News Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

St. Jude researchers solve a central mystery of a baffling high-risk leukemia
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital investigators have unraveled the origins and identified mutations associated with a perplexing form of acute leukemia. The landmark study appears today as an advance online publication in the journal Nature and lays the foundation for more effective treatment of patients with the high-risk cancer.Their treatment is complicated because MPAL does not fit cleanly into a single diagnosis, but includes features of both acute lymphoblastic leukemia and acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2018 Category: Cancer & Oncology Source Type: news

For first time in 40 years, cure for acute leukemia within reach
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia. (Source: World Pharma News)
Source: World Pharma News - August 24, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

For first time in 40 years, cure for acute leukemia within reach
(The Hebrew University of Jerusalem) Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now. As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)'s Faculty of Medicine have developed a new biological drug with a cure rate of 50 percent for lab mice with acute leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 24, 2018 Category: Cancer & Oncology Source Type: news

New Study Investigates CSF3R Mutations in Acute Myeloid Leukemia
Investigations into the CSF3R gene may help lead to better classification and precise treatment of AML. (Source: CancerNetwork)
Source: CancerNetwork - August 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Stress hormone linked to leukaemia progression
Cortisol is a key activator in a pathway that enables acute myeloid leukaemia cells to evade the immune system, according to a study published inCellular& Molecular Immunology.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 15, 2018 Category: Endocrinology Source Type: news

Medical News Today: Leukemia: Do genes influence how people respond to therapy?
Some people with acute myeloid leukemia are more responsive to chemotherapy than others. Why is this, and how can this knowledge lead to better treatments? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate treatment options for hematol
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 6, 2018 Category: Cancer & Oncology Source Type: news

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
(University of Colorado Anschutz Medical Campus) Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2018 Category: Biology Source Type: news

FDA Approves Tibsovo for Acute Myeloid Leukemia
MONDAY, July 23, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. Tibsovo's effectiveness was... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2018 Category: Pharmaceuticals Source Type: news

TIBSOVO (ivosidenib), an IDH1 Inhibitor Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia with an IDH1 Mutation, Available for Order at Biologics, Inc.
CARY, N.C. (July 23, 2018) —Biologics, Inc., a McKesson Specialty Health oncology, neurology and complex care pharmacy services company, has been selected by Agios Pharmaceuticals, Inc. to be in the limited distribution network for TIBSOVO® (ivosidenib), an IDH1 inhibitor approved by the U.S. Food a... (Source: McKesson News)
Source: McKesson News - July 23, 2018 Category: Information Technology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
Title: Tibsovo Approved for Acute Myeloid LeukemiaCategory: Health NewsCreated: 7/21/2018 12:00:00 AMLast Editorial Review: 7/23/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 23, 2018 Category: Cancer & Oncology Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 -- The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 20, 2018 Category: Drugs & Pharmacology Source Type: news

FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML FDA OKs Targeted Agent Ivosidenib for Relapsed/Refractory AML
The FDA has approved the first-in-class agent ivosidenib, which targets mutations in the IDH1 gene in acute myeloid leukemia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 20, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Cambridge's Agios wins FDA approval for second cancer drug
The FDA approved a cancer drug from Agios Pharmaceuticals Inc. on Friday after a Phase 1 clinical study found it aided a small group of patients suffering from a rare type of leukemia. Cambridge-based Agios (Nasdaq: AGIO) is developing treatments for several types of cancer, including acute myeloid meukemia, or AML. The rare blood and bone marrow disease worsens quickly and accounts for approximately one percent of cancer patients, according to the National Cancer Institute. Las t year, Agios won… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 20, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Tibsovo Approved for Acute Myeloid Leukemia
FRIDAY, July 20, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. " The use of Tibsovo is associated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2018 Category: General Medicine Source Type: news

FDA OKs Targeted Agent for Acute Myeloid Leukemia
(MedPage Today) -- Approved therapies now available for IDH1- and IDH2-mutant disease (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
FDA approves new drug for the treatment of adults with acute myeloid leukemia who have a specific genetic mutation and a companion diagnostic to detect specific mutations in the IDH1 gene in patients with AML (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 20, 2018 Category: American Health Source Type: news

FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation
The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors) and is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML. (Source: World Pharma News)
Source: World Pharma News - July 20, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia
The protein tyrosine phosphatase PTPN11 is implicated in the pathogenesis of juvenile myelomonocytic leukemia (JMML), acute myeloid leukemia (AML), and other malignancies. Activating mutations in PTPN11 increase downstream proliferative signaling and cell survival. We investigated the signaling upstream of PTPN11 in JMML and AML cells and found that PTPN11 was activated by the nonreceptor tyrosine/serine/threonine kinase TNK2 and that PTPN11-mutant JMML and AML cells were sensitive to TNK2 inhibition. In cultured human cell–based assays, PTPN11 and TNK2 interacted directly, enabling TNK2 to phosphorylate PTPN11, whic...
Source: Signal Transduction Knowledge Environment - July 17, 2018 Category: Science Authors: Jenkins, C., Luty, S. B., Maxson, J. E., Eide, C. A., Abel, M. L., Togiai, C., Nemecek, E. R., Bottomly, D., McWeeney, S. K., Wilmot, B., Loriaux, M., Chang, B. H., Tyner, J. W. Tags: STKE Research Articles Source Type: news

Researchers map 'family trees' of acute myeloid leukemia
(Comprehensive Cancer Centre Gustave Roussy) For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs to produce longer-lasting remissions and to prevent relapse. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2018 Category: International Medicine & Public Health Source Type: news

Girl who missed years of school fighting cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

New Findings Illuminate'Black Box of Leukemia'New Findings Illuminate'Black Box of Leukemia '
Researchers have identified genetic mutations that may occur years before acute myeloid leukemia actually develops, giving new clues as to how the disease begins.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Girl, 16, who missed three years of school fighting rare cancer is voted prom queen
Charlotte Jenkins, 16, from Stockport in Greater Manchester battled against a rare form of acute myeloid leukaemia to be able to sit her GCSEs and go to her end of school prom. (Source: the Mail online | Health)
Source: the Mail online | Health - July 12, 2018 Category: Consumer Health News Source Type: news

Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy
Roche today announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta  (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 12, 2018 Category: Pharmaceuticals Source Type: news

Genetic changes in blood may predict leukemia diagnosis
Studying genetic changes in blood, researchers have found a way to identify people at high risk of developing acute myeloid leukemia years before diagnosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 9, 2018 Category: Consumer Health News Source Type: news

Roots of leukemia reveal possibility of predicting people at risk
(Wellcome Trust Sanger Institute) Scientists have discovered that it is possible to identify people at high risk of developing acute myeloid leukemia (AML) years before diagnosis. Wellcome Sanger Institute researchers and collaborators found that patients with AML had genetic changes in their blood years before they suddenly developed the disease. The study published in Nature shows that further research could allow earlier detection and monitoring of people at risk of AML in the future. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

Leukemia researchers discover way to predict healthy people at risk for developing AML
(University Health Network) An international team of leukemia scientists has discovered how to predict healthy individuals at risk of developing acute myeloid leukemia (AML), an aggressive and often deadly blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 9, 2018 Category: Cancer & Oncology Source Type: news

FLT3 Inhibitor Quizartinib Improves Survival in AML FLT3 Inhibitor Quizartinib Improves Survival in AML
For the first time, a single agent has produced a survival benefit when compared to standard chemotherapy in a subgroup of patients with relapsed or refractory acute myeloid leukemia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Grants Priority Review for Pfizer ’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
June 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted the company ’s New Drug Application and granted Priority Review designation for glasdegib, an investigational oral smoothened (SMO)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 27, 2018 Category: Drugs & Pharmacology Source Type: news

University of Colorado Cancer Centers Study Shows that without “Yoga...
Researchers successfully target leukemia stem cells while leaving healthy blood stem cells unharmed, paving the way for "sea change" in the way we treat acute myeloid leukemia.(PRWeb June 14, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15553957.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2018 Category: Pharmaceuticals Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions
(University of Texas M. D. Anderson Cancer Center) Ivosidenib, an experimental drug that inhibits a protein often mutated in several cancers has been shown to be safe, resulting in durable remissions, in a study of acute myeloid leukemia (AML) with relapsed or refractory disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2018 Category: Cancer & Oncology Source Type: news

Penn-developed approach could limit toxicity of CAR T therapy in acute myeloid leukemia
(University of Pennsylvania School of Medicine) A new approach pioneered at the University of Pennsylvania's Abramson Cancer Center may provide a new path towards treating acute myeloid leukemia (AML) with CAR T cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2018 Category: Cancer & Oncology Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority R... Biopharmaceuticals, Oncology, FDA Astellas Pharma, gilteritinib, Acute Myeloid Leukemia, FLT3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 29, 2018 Category: Pharmaceuticals Source Type: news

U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
TOKYO, May 29, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. " Astellas " ) announced today that the U.S. Food and Drug Administration (FDA) has accepted, with Priority Review, the company's New Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 29, 2018 Category: Drugs & Pharmacology Source Type: news

A new Achilles' heel of blood cancer
(CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences) Acute Myeloid Leukemia is an aggressive form of blood cancer. The diseased cells often carry mutated forms of a specific gene, which is known to function within large protein networks. Applying a combination of proteomic and genomic screens, researchers at CeMM and LBI-CR identified a protein crucial for the survival of the cancer cells. When this protein is lost, AML cells stop growing and accumulate DNA damage, which makes them more sensitive to anti-cancer drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 18, 2018 Category: Cancer & Oncology Source Type: news

Single surface protein boosts multiple oncogenic pathways in acute myeloid leukemia
(Rockefeller University Press) Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia (AML) plays a much wider role in the disease than previously thought. The study, which will be published May 17 in the Journal of Experimental Medicine, raises hopes that current efforts to target this signaling protein could be a successful strategy to treat AML and other blood cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 17, 2018 Category: Biology Source Type: news

Leukemia: Five easily overlooked signs you have the condition
LEUKEMIA, or blood cancer, symptoms are not always easily detected. The condition has several forms including acute myeloid leukaemia and chronic leukemia. You should look out for these five symptoms of the condition. (Source: Daily Express - Health)
Source: Daily Express - Health - May 10, 2018 Category: Consumer Health News Source Type: news

New CAR T case study shows promise in acute myeloid leukemia
(H. Lee Moffitt Cancer Center& Research Institute) According to a case study from trial published online ahead of print in the journal Haematologica, a patient has remained cancer free for nine months after being treated with CYAD-01, followed by a bone marrow transplant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2018 Category: Cancer & Oncology Source Type: news